Tozer (p. 2029) 等人评估了新生血管性年龄相关性黄斑变性 (AMD) 患眼行补救治疗的有效性，这些患眼行单药治疗（玻璃体腔注射贝伐单抗或雷珠单抗）失败。他们发现，联合光动力治疗(PDT)及抗
Category: Peer-reviewed
Erratum
With apologies from the editorial office, the Correspondence entitled, “Gene Expression Profiling vs. TNM Classification,” which printed in the May 2013 issue (Ophthalmology 2013;120:1109) erroneously included a statement that the authors of the or…
Measuring Contrast Sensitivity Using the M&S Smart System II versus the Pelli-Robson Chart
Contrast sensitivity (CS) refers to the ability of the visual system to detect differences in luminance (i.e., brightness) between an object and its background. Assessment of CS provides valuable information in the early detection and monitoring of ocu…
Editorial Board
Posterior Iris-claw Aphakic Intraocular Lens Implantation in Children
Posterior Iris-claw Aphakic Intraocular Lens Implantation in Children is an interesting article. The authors have rightly pointed out that many complications of anterior iris claw aphakic intraocular lenses (IOL) are avoided. However, potentially the m…
Clear Lens Extraction for Angle Closure
We read with great interest the recent article by Tham et al. In their prospective study, the authors compared the results of clear lens phacoemulsification (CLP) versus trabeculectomy with mitomycin C in eyes with medically uncontrolled chronic angle…
Long-term Outcomes in Ranibizumab-Treated Patients With Retinal Vein Occlusion; The Role of Progression of Retinal Nonperfusion
Purpose: To determine the percentage of ranibizumab-treated patients with retinal vein occlusion (RVO) who had resolution of edema for at least 6 months after the last injection, along with factors and outcomes that correlate with resolution.Design: Post hoc analysis of open-label clinical trial.Methods: Twenty patients with branch RVO (BRVO) and 20 with central RVO (CRVO) received ranibizumab monthly for 3 months and as needed for recurrent/persistent macular edema, no more frequently than every 2 months. Patients still requiring injections after month 40 received scatter and grid laser photocoagulation to try to reduce the need for injections. Main outcome measures included the percentage of patients who had resolution of edema, change in best-corrected visual acuity (BCVA) from baseline, and change in area of retinal nonperfusion in central subfields.Results: Nine patients with BRVO (45%) had edema resolution from injections alone after a mean of 20.2 months, 4 resolved after addition of laser, 4 were unresolved through 72 months, and 3 exited prior to resolution. Five patients with CRVO (25%) resolved from injections alone after a mean of 14.0 months, 8 remained unresolved through 72 months despite addition of laser, and 7 exited prior to resolution. For BRVO or CRVO, there was a negative correlation between posterior retinal nonperfusion area and BCVA at months 18, 24, and 36 (P < .05).Conclusions: In patients with RVO, infrequent ranibizumab injections to control edema may not be sufficient to prevent progression of retinal nonperfusion, which may contribute to loss of visual gains.
AAO Task Force on Genetic Testing
In this era of rapidly expanding genetic medicine, the American Academy of Ophthalmology (AAO)’s recently published document of recommendations for genetic testing of inherited eye diseases comes none too soon. Guidelines for genetic testing are import…
Reporting Visual Acuities
The AJO encourages authors to report the visual acuity in the manuscript using the same nomenclature that was used in gathering the data provided they were recorded in one of the methods listed here. This table of equivalent visual acuities is provided…
Author reply
We are grateful to Spratt et al for their interest in our article, and for allowing us the opportunity to further elaborate on our study. We did observe an apparent decrease in the perceived extent of peripheral anterior synechiae (PAS) after lens e…
Reply
We appreciate the thoughtful comments of Rath and associates and agree with their assessment of the limitations of our study. We intended to examine the diagnostic yield and therapeutic benefit of nonquantitative polymerase chain reaction (PCR) in the …
Author reply
We thank Dr Fraunfelder for his comments and discussion of cryotherapy as an adjunctive treatment for pterygia. Based on the established requirements of an Ophthalmic Technology Assessment Committee (OTAC) publication, we were unable to include the top…
Reply
We appreciate the comments of García-González and Teus on our article. In the study cohort, less than 17% of the patients were dissatisfied with the outcome. It is to be noticed that the Parinaud (p) scale is a measurement at 33 cm (not at 35 cm as…
Liquid Nitrogen Cryotherapy of Pterygia
The January 2013 issue of Ophthalmology includes an article by Kaufman et al that provides an excellent review of the surgical options and adjuvants used in surgery for pterygia. Labeled as a “Report by the American Academy of Ophthalmology,” the …
Uncorrected Binocular Performance after Biaspheric Ablation Profile (PresbyMAX) for Presbyopic Corneal Treatment
Surgical correction of presbyopia continues to be one of the biggest challenges for refractive surgeons. We have read with great interest the article by Baudu and associates about the postoperative binocular visual results of LASIK using PresbyMAX, a c…
The Diagnostic Utility of Anterior Chamber Paracentesis for Polymerase Chain Reaction in Anterior Uveitis
We read with interest the article by Anwar and associates on diagnostic utility of polymerase chain reaction (PCR) in anterior uveitis. The study addresses an important diagnostic challenge in the management of infectious anterior uveitis. However, it …
Consolidated Financial Statements
Intravitreal Aflibercept Injection for Neovascular Age-Related Macular Degeneration: Ninety-Six–Week Results of the VIEW Studies – Corrected Proof
Purpose: To determine efficacy and safety of intravitreal aflibercept in patients with neovascular age-related macular degeneration (AMD) during a second year of variable dosing after a first-year fixed-dosing period.Design: Two randomized, double-masked, active-controlled, phase 3 trials.Participants: Two thousand four hundred fifty-seven patients with neovascular AMD.Methods: From baseline to week 52, patients received 0.5 mg intravitreal ranibizumab every 4 weeks (Rq4), 2 mg aflibercept every 4 weeks (2q4), 0.5 mg aflibercept every 4 weeks (0.5q4), or 2 mg aflibercept every 8 weeks (2q8) after 3 monthly injections. During weeks 52 through 96, patients received their original dosing assignment using an as-needed regimen with defined retreatment criteria and mandatory dosing at least every 12 weeks.Main Outcome Measures: Proportion of eyes at week 96 that maintained best-corrected visual acuity (BCVA; lost <15 letters from baseline); change from baseline in BCVA.Results: Proportions of eyes maintaining BCVA across treatments were 94.4% to 96.1% at week 52 and 91.5% to 92.4% at week 96. Mean BCVA gains were 8.3 to 9.3 letters at week 52 and 6.6 to 7.9 letters at week 96. Proportions of eyes without retinal fluid decreased from week 52 (60.3% to 72.4%) to week 96 (44.6% to 54.4%), and more 2q4 eyes were without fluid at weeks 52 and 96 than Rq4 eyes (difference of 10.4% [95% confidence interval {CI}, 4.9–15.9] and 9.0% [95% CI, 3.0–15.1]). Patients received on average 16.5, 16.0, 16.2, and 11.2 injections over 96 weeks and 4.7, 4.1, 4.6, and 4.2 injections during weeks 52 through 96 in the Rq4, 2q4, 0.5q4, and 2q8 groups, respectively. The number of injections during weeks 52 through 96 was lower in the 2q4 and 2q8 groups versus the Rq4 group (differences of −0.64 [95% CI, −0.89 to −0.40] and −0.55 [95% CI, −0.79 to −0.30]; P < 0.0001, post hoc analysis). Incidences of Antiplatelet Trialists’ Collaboration–defined arterial thromboembolic events were similar across group (2.4% to 3.8%) from baseline to week 96.Conclusions: All aflibercept and ranibizumab group were equally effective in improving BCVA and preventing BCVA loss at 96 weeks. The 2q8 aflibercept group was similar to ranibizumab in visual acuity outcomes during 96 weeks, but with an average of 5 fewer injections. Small losses at 96 weeks in the visual and anatomic gains seen at 52 weeks in all arms were in the range of losses commonly observed with variable dosing.Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references.
Mutations in the Mevalonate Kinase (MVK) Gene Cause Nonsyndromic Retinitis Pigmentosa – Corrected Proof
Objective: Retinitis pigmentosa (RP) is a clinically and genetically heterogeneous disorder characterized by night blindness and peripheral vision loss, and in many cases leads to blindness. Despite extensive knowledge about genes involved in the patho…
High Prevalence of Peripheral Retinal Vascular Anomalies in Family Members of Patients with Familial Exudative Vitreoretinopathy – Corrected Proof
Objective: To describe the prevalence and severity of familial exudative vitreoretinopathy (FEVR) in asymptomatic relatives of known symptomatic FEVR patients.Design: Uncontrolled and retrospective case series at a single tertiary referral vitreoretina…